COSA is pleased to announce the ASM is heading west to Perth again in 2018.
COSA’s 45th ASM will focus on gastro-intestinal (GI) cancer and mesothelioma with sub-themes of technology and genomics. The program will capture the extensive research being undertaken across these cancers, and the diversity of new treatments being trialled and implemented.
GI cancer collectively is the most common form of cancer. More than 24,000 Australians are diagnosed with it each year and 33 die from it each day. Colorectal cancer remains common. Major improvements in early diagnosis and management have improved five year survival to 69%. The outlook for some other GI cancers remains poor. For example outcomes for pancreatic cancer have not improved despite widespread research, with a five year survival rate of only 8%.
Australia has one of the highest rates of mesothelioma in the world, with 732 Australians diagnosed in 2014. Most people diagnosed with mesothelioma will die as a result of their illness. While mesothelioma is rare in other countries, its frequency in Australia is a legacy of our history of mining and using asbestos. Many talented local WA clinicians are contributing to understanding and treating this deadly disease.
As always, we intend deliver you a scientific program that is as diverse as the COSA multidisciplinary membership. We hope that many of you will submit abstracts to the program to showcase your research work!
I look forward to welcoming you to Perth.
2018 COSA ASM Convenor